NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

Jesster64, let’s unpack the term “BS,” because it’s being used as a rhetorical sledgehammer where, imho, a scalpel is needed.

“BS” implies absurdity, fabrication, or impossibility. When you label everything from “tumor agnostic” to “King Charles being treated” and “Cofer Black tracking manipulators” as “BS,” you’re not making an argument—you’re dodging one. These examples aren’t equal in credibility, and lumping them together is either intellectually lazy or disingenuous.

In regard to King Charles, the facts are clear: he was diagnosed with cancer and treated as an outpatient, but the hospital, physicians, and treatment modality have not been publicly disclosed. Dr. Keyoumars Ashkan is a renowned neuro-oncology expert, awarded an MBE in 2023, and the UK lead investigator for DCVax-L—a tumor-agnostic therapy now conditionally accessible via the NHS High Cost Drugs list. It’s not unreasonable to suggest that Ashkan could have been consulted regarding the King’s case. While there’s no evidence confirming this, the institutional proximity and mechanistic relevance make the scenario plausible. Calling it “BS” isn’t skepticism—it’s rhetorical laziness. If you want to challenge the claim, challenge the evidence. But don’t flatten nuance into nonsense.

Regarding Cofer Black, the facts are equally clear: he served as Director of the CIA’s Counterterrorism Center during one of the most pivotal periods in U.S. intelligence history and currently sits on the NWBO’s Board of Directors. His expertise spans covert operations, threat network mapping, and counter-disinformation—skills directly applicable to identifying and mitigating asymmetric market manipulation. No, he’s not personally monitoring retail posters (lol). But suggesting that someone with his background might advise on strategic intelligence, cybersecurity posture, or coordinated short attack detection isn’t absurd—it’s operationally coherent. Dismissing that as “BS” ignores the very real intersection between national security-grade intelligence and the opaque, often hostile terrain of biotech markets. If you want to refute the inference, do it with logic—not with a shrug and a label.

Both examples—Ashkan’s potential consultation and Black’s strategic relevance—are speculative and unconfirmed. But they are grounded in institutional proximity, mechanistic plausibility, and real-world accessibility. That makes them reasonable assertions, not rhetorical garbage. They may not be true—but they are not “BS.”